The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins

Chronic myeloid leukemia (CML) is a clonal malignant disease caused by the expression of BCR/ABL. MDM2 (human homolog of the murine double minute-2) inhibitors such as Nutlin-3 have been shown to induce apoptosis in a p53-dependent manner in CML cells and sensitize cells to Imatinib. Here, we demons...

Descripción completa

Detalles Bibliográficos
Autores principales: You, Liangshun, Liu, Hui, Huang, Jian, Xie, Wanzhuo, Wei, Jueying, Ye, Xiujin, Qian, Wenbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352360/
https://www.ncbi.nlm.nih.gov/pubmed/27999193
http://dx.doi.org/10.18632/oncotarget.13951

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352360/
https://www.ncbi.nlm.nih.gov/pubmed/27999193
http://dx.doi.org/10.18632/oncotarget.13951

Ejemplares similares